Chief Executive Officer
Garren is a passionate leader, entrepreneur, and antibody enthusiast. He has been on the business side of antibody discovery for a decade. After graduating from Bentley University with his bachelor’s degree in economics, finance, and marketing, he began running sales and marketing for Abpro, a start-up CRO specializing in in-vivo generation of monoclonal antibodies and proteins to support drug discovery research. In 2012, he moved on to become Manager of the Licensing and Funded Research Program division of Dyax where he managed the licensing of phage display based antibody discovery technology platforms and intellectual property portfolios. This work led him to co-found Abveris where he is now the CEO & President. At Abveris he works to provide the industry with a better antibody discovery partner, accelerating the pace of science. Outside of work, Garren enjoys spending time with his wife and young son, hiking, camping, fishing, and playing tennis.
Chief Operating Officer
Tracey Mullen is a chemical-biological engineer from MIT who began her career as an Antibody Discovery Scientist at a startup contract research organization specializing in in vivo antibody discovery. In 2013, she joined the Antibody Discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to tough targets, including leveraging the Adimab platform to generate antibodies against GPCRs. In June of 2018, Tracey joined Abveris Antibody as the Director of Antibody Discovery Operations, where she managed project design and development for in vivo discovery projects before assuming the role of Chief Operating Officer.
Chief Scientific Officer
Colby Souders, PhD provides scientific leadership for the team to guide decisions and develop innovative strategies for successful delivery of each unique project. In addition, he works to advance the antibody discovery platform at Abveris by integrating new technologies and expanding upon the current capabilities. Previously, Dr. Souders graduated with a PhD in Cell and Molecular Biology from Texas A&M and has directed antibody discovery and engineering programs at both MassBiologics of the University of Massachusetts Medical School and Kanyos Bio.
Director of Business Development
Ryan Kelly, MBA is a graduate from the Harvard Department of Molecular and Cellular Biology and the first Abveris employee. Ryan consults across diverse antibody discovery projects bridging science and business development. In his free time, Ryan can be found hiking or skiing in hard to reach places around the White Mountains.
Focus: Molecular biology
Interests: Watching movies